Skip to main content

Table 7 Hypoglycemia Outcomes by treatment phase (ITT population)

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Period 1 Period 2
Hypoglycemia Glar (N = 175) % NPH (N = 164) % OR (95%CI) Glar (N = 152) % NPH (N = 159) % OR (95%CI)
Threshold <3.1 mmol/L       
Overall hypoglycemia 18.3 15.2 1.24 (0.70-2.21) 17.1 16.4 1.06 (0.58-1.92)
Daytime hypoglycemia 12.6 9.8 1.33 (0.67-2.63) 13.2 14.5 0.90 (0.47-1.71)
Nocturnal hypoglycemia 8.0 8.5 0.93 (0.43-2.02) 4.6 6.3 0.72 (0.27-1.94)
Threshold <3.9 mmol/L       
Overall hypoglycemia 25.1 22.6 1.15 (0.70-1.90) 25.0 23.9 1.06 (0.63-1.78)
Daytime hypoglycemia 20.0 15.9 1.33 (0.76-2.32) 21.1 20.8 1.02 (0.59-1.76)
Nocturnal hypoglycemia 9.1 12.2 0.72 (0.36-1.45) 5.9 9.4 0.60 (0.26-1.43)